Progression-Free Survival – Page 2

Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer

8 months ago talkbio0Tagged Anti-HER2 therapy, Carcinoma breast stage IV, erbB-2 Receptor, Hormone Therapy, Ibrance, palbociclib, Phase 3, Progression-Free Survival, standard-of-care

IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy

Lilly’s Oral SERD Imlunestrant Shows Significant Progression-Free Survival Benefits in ER+, HER2- Advanced Breast Cancer

8 months ago talkbio0Tagged CDK4/6 inhibitor, ESR1 gene, Estrogen receptor positive, HER2-, Imlunestrant, Malignant neoplasm of breast, Mutation, Oral SERD, Progression-Free Survival, Verzenio

Imlunestrant, Verzenio, oral SERD, ER+, HER2-, advanced breast cancer, progression-free survival, ESR1 mutation, CDK4/6 inhibitor

Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial

9 months ago talkbio0Tagged Clinical Trials, Keytruda, Lynparza, ovarian neoplasm, Progression-Free Survival, Survival

Keytruda, Lynparza, ovarian cancer, clinical trial, progression-free survival, overall survival

AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback

9 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, Malignant neoplasm of prostate, Metastatic to, Phase 3 Clinical Trials, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).

AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion

9 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, CAPItello-281, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, Phase 3 trial, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)

Gritstone’s GRANITE Vaccine Shows Encouraging but Limited Benefit in Metastatic Colorectal Cancer

11 months ago talkbio0Tagged Cancer Vaccines, ctDNA, granite, Gritstone Bio, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, MSS-CRC, Neoantigen, Progression-Free Survival

Gritstone bio, GRANITE, cancer vaccine, metastatic colorectal cancer, MSS-CRC, neoantigen targeting immunotherapy, progression-free survival, ctDNA

Enhertu Demonstrates Promising Efficacy in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases

11 months ago talkbio0Tagged Deruxtecan, Enhertu, Frequency of Responses, HER2-positive metastatic breast cancer, Metastatic malignant neoplasm to brain, Progression-Free Survival, trastuzumab

Enhertu, Trastuzumab Deruxtecan, HER2-positive metastatic breast cancer, brain metastases, progression-free survival, objective response rate.

ESMO 2023: Merck’s Welireg Demonstrates Sustained PFS Benefit in Advanced Renal Cell Carcinoma, Despite Ongoing OS Concerns

11 months ago talkbio0Tagged belzutifan, Co., ESMO, LITESPARK-005 trial, Overall Survival, Progression-Free Survival, Renal Cell Carcinoma, Welireg

Merck & Co., Welireg (belzutifan), ESMO 2023, Advanced Renal Cell Carcinoma (RCC), Progression-Free Survival (PFS), Overall Survival (OS), LITESPARK-005 trial